Targeting cellular senescence for cancer therapy

Rami Abduljabbar1, Yanfei Liu2, Ali Mussa3

  • 1Department of Pharmaceutics, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013 Hunan Province, PR China.

Insights

Targeting cellular senescence shows promise for improving cancer treatments. This review explores senescence-targeting agents and their potential to enhance chemotherapy efficacy and patient quality of life.

Area of Science:

  • Oncology
  • Cellular Biology

Background:

  • Cancer remains a major global cause of death, influenced by lifestyle, environmental factors, genetics, and aging.
  • Cellular senescence, a state of stable cell cycle arrest, is emerging as a therapeutic target in oncology.
  • Harnessing senescence can potentially enhance the effectiveness of existing cancer therapies.

Purpose of the Study:

  • To review recent advancements in cancer therapy strategies that target cellular senescence.
  • To explore the efficacy of senescence-targeting agents in improving treatment outcomes.
  • To discuss the application of senescence induction in preclinical and clinical settings.

Main Methods:

  • Literature review of recent studies on senescence targeting in cancer therapy.
  • Analysis of preclinical research (in vitro and in vivo) on senescence induction.
  • Evaluation of current clinical applications and future prospects of senescence-targeting strategies.

Main Results:

  • Senescence-targeting agents demonstrate potential for improving cancer therapy outcomes.
  • Preclinical studies show promise in inducing senescence for anticancer effects.
  • Clinical translation of these strategies is advancing, though challenges remain.

Conclusions:

  • Targeting cellular senescence offers a promising avenue for enhancing anticancer therapy.
  • Further preclinical research and clinical trials are needed to optimize senescence-based treatments.
  • Successful application could improve chemotherapy efficacy, patient survival, and quality of life.

Related Concept Videos

Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K